Contract W15QKN21C0014
Regeneron Pharmaceuticals Inc · Department Of Defense · January 12, 2021
Regeneron Pharmaceuticals Inc was awarded a federal contract by Department Of Defense (Department Of The Army) on January 12, 2021 for $5.57 billion of work in biological product (except diagnostic) manufacturing. Performance is in Tarrytown, NY. It was awarded under full and open competition. The contract has been modified 7 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 29, 2022.
Contract details
- PIID
- W15QKN21C0014
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Not Competed
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Tarrytown, NY
- First action
- January 12, 2021
- Latest action
- July 29, 2022
Description
TRANSFER OF REMAINING REGEN-COV DOSES TO POTA W15QKN-16-9-1002, PROTOTYPE PROJECT MCDC 2008-005
Modification timeline
-
July 29, 2022Mod P00007$0
-
February 25, 2022Mod P00006PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19):THE GOVERNMENT IS PURCHASING 2,650,000 DOSES OF THE EMERGENCY$0
-
September 14, 2021Mod P00005PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19):THE GOVERNMENT IS PURCHASING 2,650,000 DOSES OF THE EMERGENC$2.94B
-
July 26, 2021Mod P00004COVID-19 ACTION REGENERON ADMINISTRATIVE MOD$0
-
July 8, 2021Mod P00003WAWF CLAUSE UPDATE & DODAAC TRANSFER$0
-
June 17, 2021Mod P00002UPDATE TO SECTION H SPECIAL CONTRACT REQUIREMENTS, UPDATE TO SECTION A POINTS OF CONTACT, AND UPDATE TO WAWF CLAUSE.$0
-
March 9, 2021Mod P00001ADMINISTRATIVE MODIFICATION TO CORRECT SHIP-TO DODAAC FOR INVOICING PURPOSES. ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED.$0
-
January 12, 2021Base awardPRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19): IN SUPPORT OF OPERATION WARP SPEED (OWS), THE GOVERNMENT IS$2.63B
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Greer Laboratories, Inc. | Department Of Defense | December 19, 2025 | $470.4K |
| Greer Laboratories, Inc. | Department Of Defense | December 18, 2025 | $0 |
| Lifestream Blood Bank | Department Of Defense | December 18, 2025 | $29.7K |
| Kemp Proteins, Llc | Department Of Defense | December 18, 2025 | $40.0K |
| Applied Dna Sciences, Inc. | Department Of Defense | December 15, 2025 | $1 |
| Sanofi Vaccines Us Inc. | Department Of Defense | December 12, 2025 | $486.7K |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract W15QKN21C0014?
Contract W15QKN21C0014 is a federal contract awarded to Regeneron Pharmaceuticals Inc by Department Of Defense on January 12, 2021 for $5.57 billion of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 7 times since the base award.
Who won contract W15QKN21C0014?
Regeneron Pharmaceuticals Inc won contract W15QKN21C0014 from Department Of Defense.
How much is contract W15QKN21C0014 worth?
Contract W15QKN21C0014 has obligated $5.57 billion to date.